Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a new emerging drug class in treatment of T2D that act on several targets including the pancreatic β-cell, liver, kidney, brain, and CV system (9). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.